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A B S T R A C T   
Background: Whether disease-modifying therapies (DMTs) influence cancer in multiple sclerosis (MS) is 
uncertain. 
Objectives: Assess incidence of cancer diagnosis among Norwegian MS patients compared to the general popu-
lation in 1953 to 1995 and 1996 to 2017-reflecting era before and after introduction of DMTs. 
Methods: We performed a nationwide cohort study comprising 6949 MS patients and 37,922 controls, matched 
on age, sex and county. The cohort was linked to Norwegian Cancer Registry, Cause of Death Registry and 
National Educational database. We used Poisson regression to calculate incidence rate ratio (IRR) of cancer. 
Results: During 1953–1995 MS patients had similar cancer frequency compared to controls (IRR: 1.11 (95% 
Confidence Intervals (CI): 0.90–1.37)), although MS patients had increased frequency of cancer in endocrine 
glands (IRR: 2.51 (1.27–4.93). During 1996–2017 we identified significant increased frequency of cancer among 
MS patients compared to controls (IRR: 1.38 (95% CI: 1.28–1.52): in brain (IRR: 1.97 (1.41–2.78)), meninges 
(IRR: 2.44 (1.54–3.77)), respiratory organs (IRR: 1.96 (1.49–2.63)). The excess cancer diagnosis was most 
frequent among MS patients ≥ 60 years of age (HR 1.30 (1.15–1.47)). 
Conclusion: Incidence of cancer among MS patients compared to controls was higher in 1996 to 2017, corre-
sponding in time to the introduction of DMT for MS. This was observed more frequently among MS patients older 
than 60 years of age.   
1. Introduction 
Multiple sclerosis (MS) is the most common cause of neurological 
disability among young adults. The disease affects more females than 
males (3:1) and onset of disease is averagely 33 years, followed by 
lifelong disease modifying therapy (Thompson et al., 2018). MS patients 
have increased risk of several comorbidities, including cancer, and the 
life expectancy is averagely eight years shorter than the general popu-
lation in Norway (Lunde et al., 2017). We have previously reported an 
increased risk of overall cancer among patients with MS in Norway with 
follow up from 1953 to 2017, however the reason for the increased risk 
of cancer among MS patients is still unknown (Grytten et al., 2019). 
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The first disease modifying therapies were introduced to MS patients 
in Norway in 1996, and since 2000, more than fifteen immunosup-
pressant (IS) drugs have become available. Studies have suggested 
increased adverse cancer events among patients treated with mitoxan-
trone, azathioprine and cyclophosphamide (Lebrun and Rocher, 2018). 
Although studies that confirm cancer risk are lacking, therapies such as 
cladribine, fingolimod, natalizumab or alemtuzumab are accompanied 
by warning against potential cancer risk due to their effects on the im-
mune system (Rae-Grant et al., 2018). For treatment with fingolimod, 
natalizumab, alemtuzumab, dimethyl fumarate, teriflunomide, dacli-
zumab, and ocrelizumab, a risk management plan for cancer monitoring 
is mandatory. One recent study found a possibly modest higher risk of 
cancer in patients treated with fingolimod, but not in patients treated 
with natalizumab and rituximab (Alping et al., 2020). 
During the last 60 years, survival has improved among MS patients 
(Lunde et al., 2017) Longer life expectancy can contribute to increased 
cancer prevalence due to older age and shared risk factors between MS 
and cancer, like smoking. In addition, the clinical services to follow up 
MS disease has improved and the ability to detect cancer during MS 
scans of the brain has increased considerably. 
The objectives of our study were to assess the incidence of cancer 
diagnosis among Norwegian MS patients compared to the general pop-
ulation during 1953 to 1995 and during 1996 to 2017 in a large 
nationwide cohort - before and after DMTs became routinely available in 
Norway. We hypothesized that MS patients could have an altered inci-
dence of cancer diagnosis after 1996. 
2. Methods 
The patients were retrieved from the Norwegian Multiple Sclerosis 
Registry and Biobank, and in a sample study of epidemiological data on 
MS patients born between 1930 and 1979, which were retrieved from 
previous published prevalence studies (Kampman et al., 2013). All pa-
tients were diagnosed according to the criteria of Poser or McDonald as 
described in a previous study using the same cohort of patients 
(Kampman et al., 2013). Data on up to six non-MS controls matched to 
every MS patients on sex, year of birth and area of residence were 
retrieved from Statistics Norway. The complete cohort of MS cases 
(n=6949) and population controls (n = 37,922) were linked to the 
Norwegian Cancer Registry, the Cause of Death Registry and the Na-
tional Education Database. In the Norwegian Cancer Registry, the inci-
dent malignant cases have been mandatory registered since 1953, which 
is the start of follow-up in this study. All malignant cases diagnosed 
between 1953 and 2017, the date of cancer diagnosis and the type and 
site of malignancy were extracted for the cohort of MS patients and 
controls. Table 4 appendix, shows ICD-10 codes, converted from ICD 
6–9, which have been used to identify cancer diagnosis in the analysis. 
The primary outcome was time to first diagnosis of cancer. 
For any cancer outcomes, we calculated the number of events, per-
son- time and incidence rate ratios (IRR) estimated by Poisson regression 
with 95% confidence intervals (CI). This regression model is a general-
ized linear model assuming a Poisson probability distribution, modeling 
the rare events – such as cancers – occurring independently in a given 
time-period. Each parameter in this model is estimated using the 
maximum likelihood method. The IRR is the ratio of two incidence rates, 
which is the number of events divided by the person-time at risk. Offset 
variable was person- time (years) until end of follow-up due to death, 
emigration, end of study period, or causes of loss of follow-up during 
1953 to 1995, and 1996 to 2017. We used adjusted Cox proportional 
hazard regression (reported as hazard ratios (HRs) with 95% CIs) to 
estimate the association of cancer risk in patients below or above 60 
years of age. 
Covariates were categorized as male (1), female (2), cancer diagnosis 
(Y/N = 1/0), attained educational levels into primary (10 years or less), 
secondary (11–13 years), undergraduate (14–17 years), graduate (18 
years or more), age was treated as continuous. IRRs were estimated by 
strata of sex and the estimations were adjusted for age at start of follow- 
up, county of residence and attained educational level. IRRs were esti-
mated for all site-specific cancers excluding basal cell carcinoma, which 
is not available in the Norwegian Cancer Registry, sex, and periods of 
cancer diagnosis 1953–1995 and 1996–2017. 
The at-risk-period for a cancer event started on 1. January 1953 (the 
beginning of The Norwegian Cancer Registry Coverage), and ended with 
time of diagnosis of cancer, death, emigration or 31. December 2016, 
whichever came first. The at-risk-period until 1996 started with 
following cases being alive at 1. January 1953 and subsequently 
included by birth and excluded by emigration and death and ended 31. 
December 1995, whichever came first. The at-risk-period until 2017 
started with all cases being alive on 1. January 1996 and included by 
birth and excluded by emigration or death until 1. January 2017, 
whichever came first. Table 1 shows demographic and clinical charac-
teristics of the sample. Cases being alive, not emigrated nor having 
cancer diagnosis in 1995 were followed- up continuously until 2017. 
Descriptive statistics were performed by using IBM SPSS Statistics 24 
(IBM corp., Armonk, N.Y., USA) and incidence rate ratio calculations 
were carried out by using Stata Statistical Software: Release 15 (Stata-
Corp, College Station, TX, USA). 
Ethical approval was provided by The Western Norway Regional 
Committee for Medical and Health Research Ethics (REK Vest 2016/ 
300). 
3. Results 
3.1. Total cancer risk from 1953 to 2017 
For the total period of follow-up, we calculated 3,79,868 person 
years of follow- up among 6949 MS patients and 2,110,642 person years 
among 37,918 controls. In total, we identified 4805 incident cancer 
cases, of whom 788 were MS patients and 4017 were controls. 
The total adjusted cancer incidence rate ratio (IRR) among MS pa-
tients compared to controls was 1.35 (95% confidence intervals (CI): 
1.25–1.45). Among female MS patients the cancer risk was IRR: 1.35 
(1.23–1.49) compared to female controls, and among male MS patients 
the cancer risk was IRR: 1.41 (1.18–1.54) compared to male controls. 
Mean age at overall cancer diagnosis was similar with 57.0 years (SD: 
12.0) for MS patients (n = 774) and 58.0 years (SD: 13.8) for controls (n 
= 4017) (ANOVA t-test p = 0.11). 
3.2. Cancer risk from 1953 to 1995 
For the period 1953–1995 we calculated 254,088 person years of 
follow- up among patients and 1 370,882 among controls. We identified 
964 incident cancer cases of whom 155 were MS patients and 807 were 
controls. 
From 1953 to 1995 the total cancer risk was slightly, although not 
significantly increased among MS-patients compared to controls (IRR: 
1.11, 95% CI: 0.90, 1.37) (Table 2). Among female MS patients the 
cancer risk was IRR: 1.27 (1.01, 1.59) compared to female controls, and 
among male MS patients the cancer risk was IRR: 0.68 (0.41, 1.13) 
compared to male controls (Fig. 1). A higher age was observed in MS 
patients who had 42.5 years as mean age (SD: 11.7) at overall cancer 
diagnosis in comparison to controls who had 38.3 as mean age at overall 
cancer diagnosis (n = 529) (ANOVA t- test p = 001). Mean age at cancer 
diagnosis was 36.2 (SD: 10.1) years for male MS patients and 37.0 (SD: 
13.5) years for male controls. Mean age at cancer diagnosis was 43.6 
(SD: 11.6) years for female MS patients and 38.7 (SD: 11.8) years for 
female controls. 
Although no significant overall cancer risk was observed, and 
numbers were low, we found increased cancer risk among female MS 
patients in endocrine glands (IRR: 2.51, 95% CI: 1.27, 4.93), and in 
bones, joints and mesothelium (IRR: 6.28 (1.37–28.65) and increased 
risk of cancer among male MS patients in urinary organs (IRR: 10.41 
N. Grytten et al.                                                                                                                                                                                                                                 
Multiple Sclerosis and Related Disorders 55 (2021) 103209
3
(2.33–47.61), and hematological cancers (IRR: 6.67 (1.24–35.84) 
compared to controls (Table 2). 
3.3. Cancer risk from 1996 to 2017 
For the period 1996–2017, we calculated 122,780 person years of 
follow- up among MS patients and 7,29,765 person years among con-
trols. We identified 3833 incident cancer cases, of whom 623 were MS 
patients and 3210 were controls. 
Incidence of overall cancer diagnosis was higher than expected (IRR: 
1.38; 95% CI: 1.28–1.52) (Table 3). Among female MS patients the 
cancer risk was IRR: 1.36 (1.23–1.51) compared to female controls, and 
among male MS patients the cancer risk was IRR: 1.49 (1.30–1.72) 
compared to male controls (Fig. 1). A slightly lower age was observed in 
MS patients (n = 669) who had 58.3 as mean age (SD: 10.5) in com-
parison to controls (n = 3488), who had 59.7 as mean age (SD: 11.6) at 
overall cancer diagnosis (t-test p = 0.003) (Table 1). Mean age at cancer 
diagnosis was 60.2 (SD: 10.3) years for male MS patients and 62.8 (SD: 
11.1) years for male controls. Mean age at cancer diagnosis was 57.2 
(SD: 10.3) years for female MS patients and 57.9 (SD: 11.5) years for 
female controls. 
Increased incidence was significant for brain and nervous system 
(IRR: 1.97 (1.41–2.78), meninges (IRR: 2.44, 1.54–3.77) and respiratory 
organs (IRR: 1.96, 1.49–2.63). Female MS patients had also increased 
risk of breast cancer (IRR: 1.24, 1.03–1.49), genital cancer (IRR: 1.40, 
1.09–1.80) and cancer in digestive system (IRR: 1.48, 1.13–1.92) 
Table 1 
Number of MS patients and the Norwegian general population controls with follow up 1953 to 2017, with follow up of cancer 1953 to 1995, and with follow up of 
cancer from 1996 to 2017.   
1953 to 1995 1996 to 2017  

















Sex; n (%):         
Female 488 (68) 127 (82) 2513 
(70) 
603 (75) 4150 (67) 410 (66) 22,751(66) 2014 (63) 
Male 233 (32) 28 (18) 1053 
(30) 
204 (25) 2078 (33) 213 (34) 11,601 (34) 1196 (37) 
Age at start of follow-up (years); median, 
(range) 
0 (28) 5 (23) 0 (23) 5 (23) 40 (54) 48 (48) 40 (49) 48 (49) 
Year of birth; median, (range) 1956 (54) 1956 (54) 1948 
(39) 
1956 (49) 1948 (49) 1956 (54) 1949 (48) 1956 (49) 
Age at cancer diagnosis (years); mean 
(SD)  
42.5 (11.7)  38.3 (12.3)  58.3 (10.50)  59.7 (11.6) 
Educational level:         
Primary 161 (22) 40 (26) 859 (24) 205 (25) 1448 (23) 180 (29) 8322 (24) 834 (26) 
Secondary 294 (41) 65 (42) 1202 
(34) 
342 (42) 3039 (49) 303 (49) 14690 (43) 1489 (46) 
Undergraduate level 186 (26) 32 (21) 1141 
(32) 
210 (26) 1326 (21) 100(16) 8997 (26) 682 (21) 
Graduate level 62 (9) 17 (11) 364 (10) 50 (6) 381 (6) 38(6) 2343 (0.07) 200 (6) 
Not available 18 (2) 1 (1) 7 (0.2) 0 44 (1) 2 (0.3) 0 5 (0.2)  
Table 2 
Incidence rate ratio (IRR) with 95% Confidence Interval (CI) by Poisson regression for cancer among MS patients compared to controls stratified by sex. Male MS 
patients and female MS patients compared to male controls and female controls with follow up from 1953 to 1995.   
Men (n = 14,965) Women (n = 29,902) Total (n = 44,867)  
Cancer (n) Cancer (n) Cancer (n)  
MS Control IRR (95% CI) MS Control IRR (95% CI) MS Control IRR (95% CI) 
n 2311 12,654  4638 25,264  6949 37,918  
Person years 85,451 4,62,256 
åpxflb2,256  
168,637 908,626  2,54,088 1,370,882  
All cancer 28 204 0.68 (0.41, 1. 13) 127 603 1.27 (1.01, 1.59)* 155 807 1.11 (0.90, 1.37) 
Brain; nervous system 1 24 5.85 (0.75, 45.45) 8 46 0.68 (0.20, 3.20) 9 70 0.83 (0.28, 2.45) 
Meninges 0 1 NA 5 14 0.74 (0.08, 6.49) 5 15 0.71 (0.08, 6,25) 
Breast 0 0 NA 32 142  32 142 0.76 (0.49, 1.22) 
Skin 7 31 2.08 (0.65,6.54) 16 101 0.51 (0.25,1.06) 23 132 0.69 (0.38, 1.28) 
Female genital organs - - NA 26 159 0.78 (0.48,1.27) 26 159 NA 
Male genital organs 7 59 0.37 (0.072, 1.77) - - NA 7 59 NA 
Eye and adnexa 0 2 NA 0 3 NA 0 5 NA 
Urinary organs 6 15 10.41 (2.33, 47.61) 
* 
6 17 1.27 (0.41,3.93) 12 32 2.08 (0.88, 4.87) 
Digestive system 3 18 1.19 (0.14,10.20) 11 42 0.81 (0.38,1.73) 14 60 0.84 (0.41, 1.72) 
Bones, joints, 
mesothelium 
1 8 16.94 (0.10,1.89) 4 4 6.28 (1.37, 28.65) 
* 
5 12 0.80 (0.38, 1.73) 
Endocrine glands 0 8 NA 14 39 2.69 (1.34, 5.36)* 14 47 2.51 (1.27, 4.93) 
* 
Hematological cancers† 2 27 6.67 (1.24, 35.84) * 5 40 0.74 (0.25, 2.20) 7 67 1.06 (0.43, 2.63) 
Oral cavity and larynx 0 8 NA 1 4 1.15 (0.11, 12.19) 1 12 0.96 (0.11, 8.14) 
Respiratory organs 1 3 NA 3 3 NA 4 6 NA 
Unknown 0 1 NA 1 3 NA 1 4 NA 
†Lymphoid, hematopoietic and related tissue; 
* p < 0.05; Abbreviation NA: Not Applicable due to few cases. 
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compared to female controls. Male MS patients had also increased risk of 
cancer in urinary organs (IRR: 2.47, 1.61–3.84), hematological cancers 
(IRR: 1.72, 1.09–2.71) and cancer in respiratory organs (IRR: 1.96 
(1.29–2.97) (Table 3). 
The excess cancer diagnosis was most frequent among MS patients ≥
60 years of age: overall cancer HR 1.30 (95% CI: 1.15–1.47), in brain 
HR: 1.60 (0.85–3.03), respiratory organs HR: 1.98 (95% CI: 1.41–2.79) 
during 1996–2017. 
4. Discussion 
We found an increased cancer incidence among MS patients 
compared to matched controls from the general population during 1996 
to 2017, in the era of DMT. In comparison, during 1953 to 1995, before 
the era of DMT, we did not observe a significantly increased cancer rates 
among MS patients compared to controls. 
With follow- up of cancer from 1996 to 2017, increased incidence of 
overall cancer and specifically in the brain, meninges and respiratory 
organs were found both among female and male MS patients. Among 
Fig. 1. Forest plot for incidence rate ratio with 95 % Confidence Intervals for cancer diagnosis during 1953–1995 and 1996–2017 among MS patients versus 
population controls, by sex. 
Table 3 
Incidence rate ratio (IRR) with 95% Confidence Interval (CI) by Poisson regression for cancer among MS patients compared to controls stratified by sex. Male MS 
patients and female MS patients compared to male controls and female controls with follow up from 1996 to 2017.   
Men (n = 14,927) Women (n = 29,816) Total (n = 44,743)  
Cohort (n) Cohort (n) Cohort (n)  
MS Control IRR (95% CI) MS Control IRR (95% CI) MS Control IRR (95% CI) 
Cohort: n 2295 12,632  4616 25,200  6911 37,832  
Person years 39,758 243,676  83,022 486,089  122,780 729,765  
All cancer 213 1196 1.49 (1.30, 1.72) ** 410 2014 1.36 (1.23, 1.51) ** 623 3210 1.38 (1.28, 1.52) ** 
Brain; nervous system 13 36 2.08 (1.11, 3.38)* 27 84 1.93 (1.32, 2.87) ** 40 120 1.97 (1.41, 2.78) ** 
Meninges 6 8 6.67 (2.22, 18.86)* 16 58 1.98 (1.20, 3.26) * 22 66 2.44 (1.54, 3.77) ** 
Breast 0 0  129 694 1.24 (1.03, 1.49) * 129 694  
Skin 20 130 1.42 (0.91, 2.22) 32 207 1.16 (0.82, 1.64) 52 337 1.22 (0.94, 1.61) 
Female genital organs   - 68 300 1.40 (1.09, 1.80) * 68 300  
Male genital organs 59 434 1.22 (0.94, 1.59) - - - 59 434  
Eye and adnexa 0 5 NA 0 4 NA 0 9 NA 
Urinary organs 25 98 2.47 (1.61,3.84) ** 18 81 1.57 (0.95, 2.58) 43 179 1.91 (1.38, 2.65) ** 
Digestive system 34 216 1.37 (0.96,1.97) 65 312 1.48 (1.13, 1.92) * 99 528 1.42 (1.15, 1.76) ** 
Bones, joints, mesothelium 1 16 0.41 (0.05,3.15) 1 15 0.44 (0.06, 3.33) 2 31 0.41 (0.10, 1.33) 
Endocrine glands 3 16 1.15 (0.34,3.86) 9 41 1.16 (0.59, 2.32) 12 57 1.16 (0.65, 2.09) 
Hematological cancers† 23 99 1.72 (1.09,2.71) * 18 132 0.89 (0.55, 1.45) 41 231 1.19 (0.86, 1.65) 
Oral cavity and larynx 4 23 1.22 (0.42,3.57) 4 24 1.10 (0.38, 3.17) 8 47 1.14 (0.54, 2.39) 
Respiratory organs 28 112 1.96 (1.29,2.97) * 33 113 2.06 (1.41, 3.03) ** 61 225 1.96 (1.49, 2.63) ** 
Unknown 3 11 1.78 (0.49,6.66) 6 7 7.29 (2.54, 21.27) ** 9 18 3.84 (1.77, 8.13) *  
† Lymphoid, hematopoietic and related tissue; 
* p < 0.05; 
** p < 0.001, Abbreviation NA = Not Applicable due to few cases. 
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female MS patients, the increased incidence of cancer was observed also 
in breast, genitalia and digestive organs. Among male MS patients, 
incidence of cancer was more frequently observed in urinary organs and 
hematological system during the whole follow- up from 1953 to 2017. 
Most studies have reported a slightly decreased cancer risk among 
MS patients compared to controls, with the exception of increased risk of 
developing malignancies in certain site specific cancer types such as in 
brain (Grytten et al., 2019, Hofer et al., 2010) urinary organs (Grytten 
et al., 2019, Bahmanyar et al., 2009, Ajdacic-Gross et al., 2016), ma-
lignant melanoma (Hofer et al., 2010, Norgaard et al., 2018, Nielsen 
et al., 2006), digestive and respiratory organs (Grytten et al., 2019), 
male and female genitalia, breast (Ajdacic-Gross et al., 2016, Nielsen 
et al., 2006, Koch-Henriksen, 1999, Sun et al., 2014) and lymphoma 
(Bahmanyar et al., 2009). The site-specific cancer types have been 
explained as caused by life style behavior such as smoking, and MRI 
surveillance resulting in the detection of brain and CNS cancer at an 
early stage among MS patients (Grytten et al., 2019, Bahmanyar et al., 
2009, Kingwell et al., 2012). 
By comparing cancer incidence before and after introduction of MS 
treatment, we found that the previously reported cumulative higher 
hazard ratio among MS patients compared to the general population 
(Grytten et al., 2019), is most likely attributional to cancer incidence 
after 1996. We found especially a higher cancer incidence in brain, 
meninges, urinary organs and respiratory organs among MS patients in 
the period 1996 to 2017, after DMT was introduced to MS patients. The 
increased cancer risk in respiratory and urinary organs could possibly be 
related to differences in life style behavior such as smoking which are 
more frequent among MS patients (Riise et al., 2003), and surveillance 
of MS by MRI and the ability to detect cancer in the brain and especially 
the meninges, at an early stage. 
A possible explanation of why overall cancer risk is similar between 
MS patients and controls in the period from 1953 to 1995, and higher 
among MS patients compared to controls in the period 1996 to 2017, 
might be the older cohort and the ability to detect cancer among the 
elderly. Corroborating this assumption, we found that cancer diagnoses 
during 1996–2017 was more frequently observed among MS patients 
above 60 years of age. Since MS-patients are now living longer, this 
might also have led to an increased risk of cancer in this population 
(Lunde et al., 2017). In the follow-up period from 1953 to 1995, with 
similar incidence of cancer between MS patients and controls, we found 
significant higher age at cancer diagnosis among MS patients (42.5 years 
mean age) in comparison with controls (38.3 years mean age). Contrary, 
in the follow- up period from 1996 to 2017, we found significantly lower 
age at cancer diagnosis among MS patients (58.3 years mean age) 
compared to controls (59.7 years mean age). The period 1953 to 1995 
revealed results on cancer incidence which are in concordance with 
previous studies on cancer incidence among MS patients, showing 
similar or lower incidence rates of cancer in MS (Norgaard et al., 2018, 
Hongell et al., 2019, Kingwell et al., 2012, D’Amico et al., 2019). Thus, 
the diversity in the age of the population and longevity on follow- up 
might explain the divergent results in cancer studies in MS until today. 
In the period 1996 to 2017, we found a higher incidence of cancer 
among female MS patients in breasts, genitalia and digestive systems, 
compared to female controls. One possible mechanism could be that 
suppression of the immune system might result in women’s suscepti-
bility to human papilloma virus (HPV) and cervical cancers. These 
specific cancer types were not increased among MS patients during 1953 
to 1995, in the era prior to DMT. MS patients who have developed breast 
cancer have been reported in clinical trials of interferons (Parker et al., 
2016), natalizumab (Polman et al., 2006), fingolimod (Cuvillier, 2008), 
teriflunomide (Huang et al., 2015), alemtuzumab (Coles et al., 2017)and 
cervical cancer has been observed among patients treated with natali-
zumab (Polman et al., 2006), teriflunomide (O’Connor et al., 2011) and 
cladribine (Giovannoni et al., 2010). Gastric tumors have been observed 
among MS patients treated with fingolimod (Cuvillier, 2008) and he-
matological cancers have been observed among patients treated with 
natalizumab (Mori et al., 2004) (myeloma), fingolimod (Cuvillier, 2008) 
(lymphoma), cladribine (leukemia, lymphomas) (Lee et al., 2013) and 
alemtuzumab (Demko et al., 2008) (leukemia, lymphomas). These 
medications and possible cancer risks have recently been reviewed 
(Melamed and Lee, 2019). Our observation of these cancer types being 
significantly increased among MS patients in the era of DMT compared 
to previous periods points to a possibility that these drugs might play a 
role in higher cancer incidence among MS patients compared to the 
general population. However, surveillance might also overestimate 
cancer incidence among MS- patients due to MRI being part of the 
MS-follow, in genitals and urinary tract as examinations after MS related 
issues with miction/ defecation, and hematological cancers as result of 
MS patients’ regular blood tests measuring white-blood-cells counts. 
Finally, multiple comparisons were not adjusted when estimating the 
subgroup cancer risks and these results should therefore be interpreted 
with caution. 
Although the survival of in MS has increased, MS patients have still 
on average a shorter lifetime expectancy compared to the general pop-
ulation in Norway, and cancer is a primary cause of death (Lunde et al., 
2017). In order to further improve survival, clinical awareness of cancer 
risk among MS patients, in the form of cervical screening (Nosek and 
Howland, 1997) and cancer screening in general (Cheng et al., 2001) 
could be important. 
Our study does not support a hypothesis of diagnostic neglect of 
cancer in explaining overall cancer incidence in MS. Diagnostic neglect 
and clinicians failing to identify tumors equally among MS patients and 
peers without MS, resulting in later diagnosis and initiative to treat MS 
patients suffering from cancer (Kingwell et al., 2012), cannot explain 
divergent cancer risk in this investigation. Contrary, in this longitudinal 
cohort study, we found increased cancer risk among MS patients overall, 
and specifically increased brain cancer, cancer in the meninges, and 
cervical cancer, suggesting that frequent clinical, biochemical and 
radiological monitoring might detect malignant disease, rather than 
diagnostic neglect. Particularly cancers in the brain and meninges dur-
ing 1996–2017 could be explained by ascertainment bias and the 
frequent MR scans in MS follow- up, which increases the ability to 
clinically identify tumors at early stage. The explanation for our findings 
of increased cancer in particular and cervical, breast and brain cancer 
specifically, contrary to previous reports indicating diagnostic neglect 
(Kingwell et al., 2012) can possibly be explained by the quality and 
appropriateness of data sources. In our study, we used data from the 
Norwegian Cancer Registry, which registers all cancer cases in Norway, 
contrary to Administrative data that might be prone to sampling bias 
(Kingwell et al., 2012). In addition, the Norwegian health system uni-
versally covers all citizens, with full access to diagnostic, and treatment 
Table 4 
Applied ICD-10 codes used to identify cancer diagnosis in the analysis.  
Type of cancer ICD-10 
Brain; nervous system C70, C71, C72 
Meninges C70 
Breast C50 
Skin C43, C44 
Female genital organs C51, C52, C53, C54, C55, C56, C57 + (C58) 
Male genital organs C60, C61, C62 
Eye and adnexa C69 
Urinary organs C64, C65, C66, C67, C68 




C40, C41, C45, C48, C49 
Endocrine glands C73, C74, C75 
Hematological cancers† D45, D46, D47, C81, C82, C83, C84, C85, C88, C90, C91, 
C92, C93, C94, C96 
Oral cavity and larynx C0, C1, C2, C3, C4, C5, C7, C8, C9, C12 
Respiratory organs C30, C31, C32, C33, C34, C37, C38 
Unknown C76, C80  
† Lymphoid, hematopoietic and related tissue. 
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facilities. 
Although the overall incidence of cancer among MS patients is more 
frequent after 1996 in the era of DMT, we also found a higher frequency 
of urinary – and hematological cancers among male MS patients in the 
total follow-up period from 1953 to 2017. This continuity on cancer 
excess among male MS patients seems therefore to be independent of 
DMT use, and might be a result of the MS-disease itself or common 
etiological risk factors. 
Advantages of this study is the longitudinal registry based data with 
valid and reliable data from prevalence studies and population based 
registries. This cohort of patients were collected on a more structured 
way than medical records and administrative data collected for 
administrative purposes, rather than research. The cohort has been 
validated in previous studies (Bjornevik et al., 2017, Torkildsen et al., 
2014) on MS risk factors. The Norwegian Cancer registry is an almost 
complete database (Larsen et al., 2009), the diagnostic accuracy is 
reliable and registration of cancer incidence is mandatory since 1953 to 
all clinicians in Norway. Adjustment for education as socioeconomic 
factor was made to adjust for MS outcome such as the variation of access 
to and compliance with health care utilization (Hillert, 2020) and risk of 
cancer. We also analyzed MS patients risk compared to individual 
matched controls on sex, age and county of residence. Thus, as age is a 
strong confounder of cancer risk we also adjusted the analyses for age in 
1996, in order to prevent bias concerning MS patients’ early death. The 
longitudinal design allowed for long-term observation of total cancer 
and types of cancer, which is to our knowledge a rarity among cancer 
studies in MS. 
The main limitation of our study is the lack of data on DMT use. Thus, 
we are not able to verify if the increased cancer incidence during the last 
decades is caused by individual DMT use. Further, we do not have data 
to determine if some of the DMTs are associated with increased cancer 
risk compared to others. In the analyses we adjusted for education as a 
proxy for socioeconomic status shown to be important in assessment of 
MS outcome (Hillert, 2020). The main limitation regarding this adjust-
ment was that we did not have individual behavioral data of life style 
risk factors for cancer, such as smoking, BMI and nutrition. 
5. Conclusion 
We found significantly increased overall cancer risk among MS pa-
tients during 1996 to 2017, in the era of introduction of DMT in Norway. 
Particularly, cancer in the brain, meninges and respiratory organs was 
increased for both female and male MS patients. This increased fre-
quency of cancer diagnosis in the brain and meninges could be due to 
improved ascertainment on MR-screenings. Because of improved sur-
vival and longer life expectancy, MS patients are more susceptible to 
cancer diagnosis, and clinicians should be aware of the increased risk of 
cancer among MS patients above 60 years of age. To determine the role 
of long-term use of specific DMT in cancer risk, further longitudinal data 
is necessary. 
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